{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:52:01Z","timestamp":1785909121797,"version":"3.56.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"DOI":"10.1007\/s00428-026-04658-0","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:38:16Z","timestamp":1785908296000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transforming routine solid tumor profiling with automated next-generation sequencing: experience from a reference general hospital"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5388-0353","authenticated-orcid":false,"given":"Annarita","family":"Destro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Panebianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cec\u00edlia","family":"Dur\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Quagliata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Rudini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreina","family":"Salvati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Lo","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Piombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Uccella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Terracciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"4658_CR1","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","volume":"35","author":"MF Mosele","year":"2024","unstructured":"Mosele MF, Westphalen CB, Stenzinger A, Barlesi F, Bayle A, Bieche I, Bonastre J, Castro E, Dienstmann R, Kramer A, Czarnecka AM, Meric-Bernstam F, Michiels S, Miller R, Normanno N, Reis-Filho J, Remon J, Robson M, Rouleau E, Scarpa A, Serrano C, Mateo J, Andre F (2024) Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine. Working Group Ann Oncol 35:588\u2013606. https:\/\/doi.org\/10.1016\/j.annonc.2024.04.005","journal-title":"Working Group Ann Oncol"},{"key":"4658_CR2","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1158\/1078-0432.CCR-21-2384","volume":"28","author":"H Verdaguer","year":"2022","unstructured":"Verdaguer H, Sauri T, Acosta DA, Guardiola M, Sierra A, Hernando J, Nuciforo P, Miquel JM, Molero C, Peiro S, Serra-Camprubi Q, Villacampa G, Aguilar S, Vivancos A, Tabernero J, Dienstmann R, Macarulla T (2022) ESMO scale for clinical actionability of molecular targets driving targeted treatment in patients with cholangiocarcinoma. Clin Cancer Res 28:1662\u20131671. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2384","journal-title":"Clin Cancer Res"},{"key":"4658_CR3","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","volume":"29","author":"J Mateo","year":"2018","unstructured":"Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard JY, Van Allen EM, Schultz N, Swanton C, Andre F, Pusztai L (2018) A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol 29:1895\u20131902. https:\/\/doi.org\/10.1093\/annonc\/mdy263","journal-title":"Ann Oncol"},{"key":"4658_CR4","doi-asserted-by":"publisher","first-page":"e2100484","DOI":"10.1200\/PO.21.00484","volume":"6","author":"P Martin-Romano","year":"2022","unstructured":"Martin-Romano P, Mezquita L, Hollebecque A, Lacroix L, Rouleau E, Gazzah A, Bahleda R, Planchard D, Varga A, Baldini C, Postel-Vinay S, Friboulet L, Loriot Y, Verlingue L, Geraud A, Camus MN, Nicotra C, Soria JC, Andre F, Besse B, Massard C, Italiano A (2022) Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology. JCO Precis Oncol 6:e2100484. https:\/\/doi.org\/10.1200\/PO.21.00484","journal-title":"JCO Precis Oncol"},{"key":"4658_CR5","doi-asserted-by":"publisher","first-page":"e24977","DOI":"10.1002\/jcla.24977","volume":"37","author":"H Chen","year":"2023","unstructured":"Chen H, Wang B, Zhang Y, Shu Y, Dong H, Zhao Q, Yang C, Li J, Duan X, Zhou Q (2023) A unified DNA- and RNA-based NGS strategy for the analysis of multiple types of variants at the dual nucleic acid level in solid tumors. J Clin Lab Anal 37:e24977. https:\/\/doi.org\/10.1002\/jcla.24977","journal-title":"J Clin Lab Anal"},{"key":"4658_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.lungcan.2021.08.008","volume":"161","author":"DA Moore","year":"2021","unstructured":"Moore DA, Benafif S, Poskitt B, Argue S, Lee SM, Ahmad T, Papadatos-Pastos D, Jamal-Hanjani M, Bennett P, Forster MD (2021) Optimising fusion detection through sequential DNA and RNA molecular profiling of non-small cell lung. cancer Lung Cancer 161:55\u201359. https:\/\/doi.org\/10.1016\/j.lungcan.2021.08.008","journal-title":"cancer Lung Cancer"},{"key":"4658_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.6004\/jnccn.2023.0002","volume":"21","author":"C Horbinski","year":"2023","unstructured":"Horbinski C, Nabors LB, Portnow J, Baehring J, Bhatia A, Bloch O, Brem S, Butowski N, Cannon DM, Chao S, Chheda MG, Fabiano AJ, Forsyth P, Gigilio P, Hattangadi-Gluth J, Holdhoff M, Junck L, Kaley T, Merrell R, Mrugala MM, Nagpal S, Nedzi LA, Nevel K, Nghiemphu PL, Parney I, Patel TR, Peters K, Puduvalli VK, Rockhill J, Rusthoven C, Shonka N, Swinnen LJ, Weiss S, Wen PY, Willmarth NE, Bergman MA, Darlow S (2023) NCCN Guidelines(R) Insights: Central Nervous System Cancers, Version 2.2022. J Natl Compr Canc Netw 21:12\u201320. https:\/\/doi.org\/10.6004\/jnccn.2023.0002","journal-title":"J Natl Compr Canc Netw"},{"key":"4658_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.6004\/jnccn.2025.0042","volume":"23","author":"AB Benson 3rd","year":"2025","unstructured":"Benson AB 3rd, D\u2019Angelica MI, Abrams T, Ahmed A, Akce M, Anaya DA, Anders R, Are C, Aye L, Bachini M, Baker M, Binder D, Brown DB, Burgoyne A, Castellanos J, Cloyd J, Cullinan D, Franses J, Glazer ES, Harris W, Iyer R, Jennings L, Kelley RK, Khan S, Levine M, Melstrom L, Palta M, Raman S, Ronnekleiv-Kelly S, Sahai V, Stein S, Stephans K, Thanikachalam K, Turk A, Vauthey JN, Venook AP, Yano M, Yopp A, Zhao K, Schonfeld R, Hochstetler C (2025) Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw 23:403\u2013418. https:\/\/doi.org\/10.6004\/jnccn.2025.0042","journal-title":"J Natl Compr Canc Netw"},{"key":"4658_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Desai AP, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Juloori A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Mullikin TC, Ng T, Owen D, Owen DH, Patel SP, Patil T, Polanco PM, Riess J, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM, Hang L (2024) Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 22:249\u2013274. https:\/\/doi.org\/10.6004\/jnccn.2204.0023","journal-title":"J Natl Compr Canc Netw"},{"key":"4658_CR10","doi-asserted-by":"publisher","first-page":"100840","DOI":"10.1016\/j.lanepe.2024.100840","volume":"38","author":"I Houda","year":"2024","unstructured":"Houda I, Dickhoff C, Uyl-de Groot CA, Reguart N, Provencio M, Levy A, Dziadziuszko R, Pompili C, Di Maio M, Thomas M, Brunelli A, Popat S, Senan S, Bahce I (2024) New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe. Lancet Reg Health Eur 38:100840. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100840","journal-title":"Lancet Reg Health Eur"},{"key":"4658_CR11","doi-asserted-by":"publisher","first-page":"100839","DOI":"10.1016\/j.lanepe.2024.100839","volume":"38","author":"V de Jager","year":"2024","unstructured":"de Jager V, Wim T, Arnaud B, Johan B, Luka B, Reinhard B, Maria Gabriela OF, Havel L, Maximilian JH, Paul H, Annelies J, Kempen LVv, Izidor K, Jos\u00e9 Carlos M, Mohor\u010di\u010d K, Sanjay P, Ale\u0161 R, Wolf J, Schuuring E, Wekken A (2024) Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer. Lancet Reg Health Eur 38:100839. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100839","journal-title":"Lancet Reg Health Eur"},{"key":"4658_CR12","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.3390\/cancers15061635","volume":"15","author":"E O\u2019Sullivan","year":"2023","unstructured":"O\u2019Sullivan E, Keogh A, Henderson B, Finn SP, Gray SG, Gately K (2023) Treatment strategies for KRAS-mutated non-small-cell lung cancer Cancers. (Basel) 15:1635. https:\/\/doi.org\/10.3390\/cancers15061635","journal-title":"(Basel)"},{"key":"4658_CR13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, Peters S, Planchard D, Smit EF, Solomon BJ, Veronesi G, Reck M (2023) Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 34:339\u2013357. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.009","journal-title":"Ann Oncol"},{"key":"4658_CR14","doi-asserted-by":"publisher","first-page":"100838","DOI":"10.1016\/j.lanepe.2024.100838","volume":"38","author":"V de Jager","year":"2024","unstructured":"de Jager V, Wim T, Arnaud B, Johan B, Luka B, Reinhard B, Maria Gabriela OF, Havel L, Maximilian JH, Paul H, Annelies J, Mikael J, Kempen LVv, Izidor K, L\u00f3pez-Rios F, Margreet L, Jos\u00e9 Carlos M, Mohor\u010di\u010d K, Paz-Ares L, Sanjay P, Ale\u0161 R, Taniere P, Wolf J, Schuuring E, Wekken A (2024) Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries. Lancet Reg Health Eur 38:100838. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100838","journal-title":"Lancet Reg Health Eur"},{"key":"4658_CR15","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/annonc\/mdz204","volume":"30","author":"C Marchio","year":"2019","unstructured":"Marchio C, Scaltriti M, Ladanyi M, Iafrate AJ, Bibeau F, Dietel M, Hechtman JF, Troiani T, Lopez-Rios F, Douillard JY, Andre F, Reis-Filho JS (2019) ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol 30:1417\u20131427. https:\/\/doi.org\/10.1093\/annonc\/mdz204","journal-title":"Ann Oncol"},{"key":"4658_CR16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1200\/GO.2023.9.Supplement_1.54","volume":"9","author":"R Patel","year":"2023","unstructured":"Patel R, Chitkara A, Patel Z, Patel F, Patel M, Anamika F, Kuvani H, Thawani R (2023) Efficacy of fibroblast growth factor receptor (FGFR) inhibitors therapy in advanced cholangiocarcinoma with FGFR genes alterations: A meta-analysis of phase II clinical trials. JCO Global Oncol 9:54\u201354. https:\/\/doi.org\/10.1200\/GO.2023.9.Supplement_1.54","journal-title":"JCO Global Oncol"},{"key":"4658_CR17","doi-asserted-by":"publisher","first-page":"923","DOI":"10.21037\/hbsn-23-476","volume":"12","author":"R Khoury","year":"2023","unstructured":"Khoury R, Khalife N, Ibrahim R, Saleh K (2023) Futibatinib: new targeted therapy in intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 12:923\u2013926. https:\/\/doi.org\/10.21037\/hbsn-23-476","journal-title":"Hepatobiliary Surg Nutr"},{"key":"4658_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","volume":"23","author":"PY Wen","year":"2022","unstructured":"Wen PY, Stein A, van den Bent M, De Greve J, Wick A, de Vos F, von Bubnoff N, van Linde ME, Lai A, Prager GW, Campone M, Fasolo A, Lopez-Martin JA, Kim TM, Mason WP, Hofheinz RD, Blay JY, Cho DC, Gazzah A, Pouessel D, Yachnin J, Boran A, Burgess P, Ilankumaran P, Gasal E, Subbiah V (2022) Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol 23:53\u201364. https:\/\/doi.org\/10.1016\/S1470-2045(21)00578-7","journal-title":"Lancet Oncol"},{"key":"4658_CR19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.path.2021.05.003","volume":"14","author":"K Galbraith","year":"2021","unstructured":"Galbraith K, Snuderl M (2021) Molecular pathology of gliomas. Surg Pathol Clin 14:379\u2013386. https:\/\/doi.org\/10.1016\/j.path.2021.05.003","journal-title":"Surg Pathol Clin"},{"key":"4658_CR20","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s40265-024-02097-2","volume":"84","author":"YN Lamb","year":"2024","unstructured":"Lamb YN (2024) Vorasidenib: First Approval Drugs 84:1325\u20131331. https:\/\/doi.org\/10.1007\/s40265-024-02097-2","journal-title":"Vorasidenib: First Approval Drugs"},{"key":"4658_CR21","doi-asserted-by":"publisher","unstructured":"Fassan M, Angerilli V, Nicola N, Pruneri G, Antonio M, Grillo F, Tonini G, Scarpa A, Rimassa L (2024) Practical guidelines for molecular testing of cholangiocarcinoma in clinical practice: Italian experts\u2019 position paper Crit Rev Oncol Hematol:104224. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104224","DOI":"10.1016\/j.critrevonc.2023.104224"},{"key":"4658_CR22","doi-asserted-by":"publisher","first-page":"42478","DOI":"10.18632\/oncotarget.17199","volume":"8","author":"M Cho","year":"2017","unstructured":"Cho M, Ahn S, Hong M, Bang H, Van Vrancken M, Kim S, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Sun JM, Lee SH, Ahn MJ, Park K, Kim DH, Lee S, Park W, Kim KM (2017) Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center. \u2018s experiences Oncotarget 8:42478\u201342486. https:\/\/doi.org\/10.18632\/oncotarget.17199","journal-title":"\u2019s experiences Oncotarget"},{"key":"4658_CR23","doi-asserted-by":"publisher","first-page":"101628","DOI":"10.1016\/j.esmoop.2023.101628","volume":"8","author":"P Hofman","year":"2023","unstructured":"Hofman P, Calabrese F, Kern I, Adam J, Alarcao A, Alborelli I, Anton NT, Arndt A, Avdalyan A, Barberis M, Begueret H, Bisig B, Blons H, Bostrom P, Brcic L, Bubanovic G, Buisson A, Calio A, Cannone M, Carvalho L, Caumont C, Cayre A, Chalabreysse L, Chenard MP, Conde E, Copin MC, Cote JF, D\u2019Haene N, Dai HY, de Leval L, Delongova P, Dencic-Fekete M, Fabre A, Ferenc F, Forest F, de Fraipont F, Garcia-Martos M, Gauchotte G, Geraghty R, Guerin E, Guerrero D, Hernandez S, Hurnik P, Jean-Jacques B, Kashofer K, Kazdal D, Lantuejoul S, Leonce C, Lupo A, Malapelle U, Matej R, Merlin JL, Mertz KD, Morel A, Mutka A, Normanno N, Ovidiu P, Panizo A, Papotti MG, Parobkova E, Pasello G, Pauwels P, Pelosi G, Penault-Llorca F, Picot T, Piton N, Pittaro A, Planchard G, Pote N, Radonic T, Rapa I, Rappa A, Roma C, Rot M, Sabourin JC, Salmon I, Prince SS, Scarpa A, Schuuring E, Serre I, Siozopoulou V, Sizaret D, Smojver-Jezek S, Solassol J, Steinestel K, Stojsic J, Syrykh C, Timofeev S, Troncone G, Uguen A, Valmary-Degano S, Vigier A, Volante M, Wahl SGF, Stenzinger A, Ilie M (2023) Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe. ESMO Open 8:101628. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101628","journal-title":"ESMO Open"},{"key":"4658_CR24","doi-asserted-by":"publisher","DOI":"10.3791\/65190","author":"C Bontoux","year":"2023","unstructured":"Bontoux C, Lespinet-Fabre V, Bordone O, Tanga V, Allegra M, Salah M, Lalvee S, Goffinet S, Benzaquen J, Marquette CH, Ilie M, Hofman V, Hofman P (2023) Ultra-fast amplicon-based next-generation sequencing in non-squamous non-small cell lung. cancer J Vis Exp:e65190. https:\/\/doi.org\/10.3791\/65190","journal-title":"cancer J Vis Exp:e65190"},{"key":"4658_CR25","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.3390\/curroncol31030115","volume":"31","author":"KE Fleming","year":"2024","unstructured":"Fleming KE, Hupel A, Mithoowani H, Lulic-Kuryllo T, Valdes M (2024) Biomarker turnaround times and impact on treatment decisions in patients with advanced non-small cell lung carcinoma at a large Canadian community hospital with an affiliated regional cancer centre. Curr Oncol 31:1515\u20131528. https:\/\/doi.org\/10.3390\/curroncol31030115","journal-title":"Curr Oncol"},{"key":"4658_CR26","doi-asserted-by":"publisher","first-page":"711","DOI":"10.21037\/tlcr-21-981","volume":"11","author":"SK Low","year":"2022","unstructured":"Low SK, Ariyasu R, Uchibori K, Hayashi R, Chan HT, Chin YM, Akita T, Harutani Y, Kiritani A, Tsugitomi R, Manabe R, Ogusu S, Amino Y, Kitazono S, Yanagitani N, Nakamura Y, Nishio M (2022) Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with Genexus integrated sequencer Transl. Lung Cancer Res 11:711\u2013721. https:\/\/doi.org\/10.21037\/tlcr-21-981","journal-title":"Lung Cancer Res"},{"key":"4658_CR27","doi-asserted-by":"publisher","first-page":"103929","DOI":"10.1016\/j.critrevonc.2023.103929","volume":"184","author":"MG Ferrara","year":"2023","unstructured":"Ferrara MG, Belluomini L, Smimmo A, Sposito M, Avancini A, Giannarelli D, Milella M, Pilotto S, Bria E (2023) Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors. Crit Rev Oncol Hematol 184:103929. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.103929","journal-title":"Crit Rev Oncol Hematol"},{"key":"4658_CR28","doi-asserted-by":"publisher","first-page":"5822","DOI":"10.21037\/jtd-20-1630","volume":"12","author":"X Gao","year":"2020","unstructured":"Gao X, Wei XW, Zheng MY, Chen ZH, Zhang XC, Zhong WZ, Yang JJ, Wu YL, Zhou Q (2020) Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer. J Thorac Dis 12:5822\u20135832. https:\/\/doi.org\/10.21037\/jtd-20-1630","journal-title":"J Thorac Dis"},{"key":"4658_CR29","doi-asserted-by":"publisher","first-page":"902664","DOI":"10.3389\/fonc.2022.902664","volume":"12","author":"H Yang","year":"2022","unstructured":"Yang H, Wen L, Zhao C, Li X, Shan C, Liu D, Hong W, Zhou Z, Zhou C, Cai L, Zhou C (2022) EGFR amplification is a putative resistance mechanism for NSCLC-LM patients with TKI therapy and is associated with poor outcome. Front Oncol 12:902664. https:\/\/doi.org\/10.3389\/fonc.2022.902664","journal-title":"Front Oncol"},{"key":"4658_CR30","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jmoldx.2025.02.001","volume":"27","author":"I Rapa","year":"2025","unstructured":"Rapa I, Bertola F, Roversi G, Seminati D, Panebianco F, Duraes C, Gallo E, Leone BE, Palange A, Righi L, Visca P, Volante M, Buglioni S (2025) Impact and Reproducibility of In-House Targeted Next-Generation Sequencing Biomarker Testing in Non-Small-Cell Lung Cancer: An Italian Multi-Institutional Experience. J Mol Diagn 27:371\u2013382. https:\/\/doi.org\/10.1016\/j.jmoldx.2025.02.001","journal-title":"J Mol Diagn"},{"key":"4658_CR31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12920-022-01214-y","volume":"15","author":"KD Doig","year":"2022","unstructured":"Doig KD, Love CG, Conway T, Seleznev A, Ma D, Fellowes A, Blombery P, Fox SB (2022) Findings from precision oncology in the clinic: rare, novel variants are a significant contributor to scaling molecular diagnostics. BMC Med Genomics 15:70. https:\/\/doi.org\/10.1186\/s12920-022-01214-y","journal-title":"BMC Med Genomics"},{"key":"4658_CR32","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1136\/jcp-2022-208625","volume":"77","author":"R Werner","year":"2024","unstructured":"Werner R, Connolly A, Bennett M, Hand CK, Burke L (2024) Implementation of an ISO15189 accredited next-generation sequencing service with the fully automated Ion Torrent Genexus: the experience of a clinical diagnostic laboratory. J Clin Pathol 77:278\u2013283. https:\/\/doi.org\/10.1136\/jcp-2022-208625","journal-title":"J Clin Pathol"},{"key":"4658_CR33","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41576-022-00551-z","volume":"24","author":"B Berger","year":"2023","unstructured":"Berger B, Yu YW (2023) Navigating bottlenecks and trade-offs in genomic data analysis. Nat Rev Genet 24:235\u2013250. https:\/\/doi.org\/10.1038\/s41576-022-00551-z","journal-title":"Nat Rev Genet"},{"key":"4658_CR34","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/jamia\/ocac197","volume":"30","author":"T Zayas-Caban","year":"2022","unstructured":"Zayas-Caban T, Okubo TH, Posnack S (2022) Priorities to accelerate workflow automation in health care. J Am Med Inf Assoc 30:195\u2013201. https:\/\/doi.org\/10.1093\/jamia\/ocac197","journal-title":"J Am Med Inf Assoc"},{"key":"4658_CR35","doi-asserted-by":"publisher","first-page":"e70304","DOI":"10.1111\/1759-7714.70304","volume":"17","author":"S Murakami","year":"2026","unstructured":"Murakami S, Hiroshima Y, Katakura S, Kondo T, Kato T, Yokose T, Saito H (2026) Clinical Utility of Comprehensive Genomic Profiling for Advanced Non-Small Cell Lung Cancer: A Single-Center Retrospective. Study Thorac Cancer 17:e70304. https:\/\/doi.org\/10.1111\/1759-7714.70304","journal-title":"Study Thorac Cancer"},{"key":"4658_CR36","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1093\/jnci\/djaf015","volume":"117","author":"I Zerdes","year":"2025","unstructured":"Zerdes I, Filis P, Fountoukidis G, El-Naggar AI, Kalofonou F, D\u2019Alessio A, Pouptsis A, Foukakis T, Pentheroudakis G, Ahlgren J, Smith D, Valachis A (2025) Comprehensive genome profiling for treatment decisions in patients with metastatic tumors: real-world evidence meta-analysis and registry data implementation. J Natl Cancer Inst 117:1117\u20131124. https:\/\/doi.org\/10.1093\/jnci\/djaf015","journal-title":"J Natl Cancer Inst"},{"key":"4658_CR37","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2217\/fon-2021-1040","volume":"18","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, Vioix H, Liu FX, Singh B, Sharma S, Sharda D (2022) Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review. Future Oncol 18:505\u2013518. https:\/\/doi.org\/10.2217\/fon-2021-1040","journal-title":"Future Oncol"},{"key":"4658_CR38","doi-asserted-by":"publisher","first-page":"e2200546","DOI":"10.1200\/PO.22.00546","volume":"7","author":"E Arriola","year":"2023","unstructured":"Arriola E, Bernabe R, Campelo RG, Biscuola M, Enguita AB, Lopez-Rios F, Martinez R, Mezquita L, Palanca S, Pareja MJ, Zugazagoitia J, Arrabal N, Garcia JF, Carcedo D, de Alava E (2023) Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non-Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers. JCO Precis Oncol 7:e2200546. https:\/\/doi.org\/10.1200\/PO.22.00546","journal-title":"JCO Precis Oncol"},{"key":"4658_CR39","doi-asserted-by":"publisher","unstructured":"Seminati D, L\u2019Imperio V, Casati G, Ceku J, Pilla D, Scalia CR, Gragnano G, Pepe F, Pisapia P, Sala L, Cortinovis DL, Bono F, Malapelle U, Troncone G, Novello S, Pagni F (2024) Economic assessment of NGS testing workflow for NSCLC in a healthcare setting Heliyon. 10:e29272. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e29272","DOI":"10.1016\/j.heliyon.2024.e29272"},{"key":"4658_CR40","doi-asserted-by":"publisher","first-page":"101893","DOI":"10.1016\/j.rmcr.2023.101893","volume":"45","author":"H Takahashi","year":"2023","unstructured":"Takahashi H, Ogino H, Bando H, Mitsuhashi A, Tsukazaki Y, Yabuki Y, Ozaki R, Yoneda H, Sato S, Hanibuchi M, Nishioka Y (2023) FoundationOne CDx detected an uncovered variant of epidermal growth factor receptor exon 19 deletion by Oncomine Dx target test in a patient with lung adenocarcinoma. Respir Med Case Rep 45:101893. https:\/\/doi.org\/10.1016\/j.rmcr.2023.101893","journal-title":"Respir Med Case Rep"},{"key":"4658_CR41","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.2147\/ott.s328839","volume":"14","author":"W Zhuang","year":"2021","unstructured":"Zhuang W, Zhang C, Tang Y, Tian D, Lan Z, Qiao G (2021) Clinical and pathologic complete response to gefitinib in a patient with SqCLC harboring EGFR p.E746_S752delinsV mutation OncoTargets. Therapy 14:4805\u20134808. https:\/\/doi.org\/10.2147\/ott.s328839","journal-title":"Therapy"},{"key":"4658_CR42","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","volume":"389","author":"C Zhou","year":"2023","unstructured":"Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourao Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N, Investigators P (2023) Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions N. Engl J Med 389:2039\u20132051. https:\/\/doi.org\/10.1056\/NEJMoa2306441","journal-title":"Engl J Med"},{"key":"4658_CR43","doi-asserted-by":"publisher","unstructured":"Canale M, Petracci E, Delmonte A, Bronte G, Chiadini E, Ludovini V, Dubini A, Papi M, Baglivo S, De Luigi N, Verlicchi A, Chiari R, Landi L, Metro G, Burgio MA, Crino L, Ulivi P (2020) Concomitant TP53 mutation confers worse prognosis in egfr-mutated non-small cell lung cancer patients treated with TKIs. J Clin Med 9. https:\/\/doi.org\/10.3390\/jcm9041047","DOI":"10.3390\/jcm9041047"},{"key":"4658_CR44","doi-asserted-by":"publisher","unstructured":"Le X, Molife C, Leusch MS, Rizzo MT, Peterson PM, Caria N, Chen Y, Gugel EG, Visseren-Grul C (2022) TP53 co-mutation status association with clinical outcomes in patients with EGFR-mutant non-small cell lung cancer. Cancers (Basel) 14. https:\/\/doi.org\/10.3390\/cancers14246127","DOI":"10.3390\/cancers14246127"},{"key":"4658_CR45","doi-asserted-by":"publisher","unstructured":"Canale M, Andrikou K, Priano I, Cravero P, Pasini L, Urbini M, Delmonte A, Crino L, Bronte G, Ulivi P (2022) The role of TP53 mutations in EGFR-mutated non-small-cell lung cancer: clinical significance and implications for therapy cancers (Basel) 14. https:\/\/doi.org\/10.3390\/cancers14051143","DOI":"10.3390\/cancers14051143"},{"key":"4658_CR46","doi-asserted-by":"publisher","first-page":"5665","DOI":"10.2147\/CMAR.S201513","volume":"11","author":"H Hou","year":"2019","unstructured":"Hou H, Qin K, Liang Y, Zhang C, Liu D, Jiang H, Liu K, Zhu J, Lv H, Li T, Zhang X (2019) Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC. Cancer Manag Res 11:5665\u20135675. https:\/\/doi.org\/10.2147\/CMAR.S201513","journal-title":"Cancer Manag Res"},{"key":"4658_CR47","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12885-020-06805-5","volume":"20","author":"K Qin","year":"2020","unstructured":"Qin K, Hou H, Liang Y, Zhang X (2020) Prognostic value of TP53 concurrent mutations for EGFR-TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis. BMC Cancer 20:328. https:\/\/doi.org\/10.1186\/s12885-020-06805-5","journal-title":"BMC Cancer"},{"key":"4658_CR48","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejca.2022.12.010","volume":"181","author":"LM Hondelink","year":"2023","unstructured":"Hondelink LM, Ernst SM, Atmodimedjo P, Cohen D, Wolf JL, Dingemans AC, Dubbink HJ, von der Thusen JH (2023) Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy. Eur J Cancer 181:53\u201361. https:\/\/doi.org\/10.1016\/j.ejca.2022.12.010","journal-title":"Eur J Cancer"},{"key":"4658_CR49","doi-asserted-by":"publisher","first-page":"e106053","DOI":"10.1371\/journal.pone.0106053","volume":"9","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Wang T, Zhang J, Cai X, Pan C, Long Y, Chen J, Zhou C, Yin X (2014) Prognostic value of epidermal growth factor receptor mutations in resected non-small cell lung cancer: a systematic review with meta-analysis. PLoS ONE 9:e106053. https:\/\/doi.org\/10.1371\/journal.pone.0106053","journal-title":"PLoS ONE"},{"key":"4658_CR50","doi-asserted-by":"publisher","first-page":"185","DOI":"10.21037\/jtd-21-1921","volume":"14","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Li S, Lyu Z, Cai J, Zheng N, Li Y, Xu T, Zeng H (2022) The co-mutation of EGFR and tumor-related genes leads to a worse prognosis and a higher level of tumor mutational burden in Chinese non-small cell lung cancer patients. J Thorac Dis 14:185\u2013193. https:\/\/doi.org\/10.21037\/jtd-21-1921","journal-title":"J Thorac Dis"},{"key":"4658_CR51","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.22.02186","volume":"41","author":"RS Herbst","year":"2023","unstructured":"Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J, Kato T, Goldman JW, Laktionov K, Kim SW, Yu CJ, Vu HV, Lu S, Lee KY, Mukhametshina G, Akewanlop C, de Marinis F, Bonanno L, Domine M, Shepherd FA, Urban D, Huang X, Bolanos A, Stachowiak M, Tsuboi M (2023) Adjuvant osimertinib for resected EGFR-mutated Stage IB-IIIA non-small-cell lung cancer: Updated results from the phase III randomized ADAURA trial. J Clin Oncol 41:1830\u20131840. https:\/\/doi.org\/10.1200\/JCO.22.02186","journal-title":"J Clin Oncol"},{"key":"4658_CR52","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-024-00566-0","volume":"12","author":"A Friedlaender","year":"2024","unstructured":"Friedlaender A, Perol M, Banna GL, Parikh K, Addeo A (2024) Oncogenic alterations in advanced NSCLC: a molecular super-highway. Biomark Res 12:24. https:\/\/doi.org\/10.1186\/s40364-024-00566-0","journal-title":"Biomark Res"},{"key":"4658_CR53","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1158\/1078-0432.CCR-20-4772","volume":"27","author":"GD Jones","year":"2021","unstructured":"Jones GD, Caso R, Tan KS, Mastrogiacomo B, Sanchez-Vega F, Liu Y, Connolly JG, Murciano-Goroff YR, Bott MJ, Adusumilli PS, Molena D, Rocco G, Rusch VW, Sihag S, Misale S, Yaeger R, Drilon A, Arbour KC, Riely GJ, Rosen N, Lito P, Zhang H, Lyden DC, Rudin CM, Jones DR, Li BT, Isbell JM (2021) KRAS (G12C) mutation is associated with increased risk of recurrence in surgically resected lung adenocarcinoma. Clin Cancer Res 27:2604\u20132612. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4772","journal-title":"Clin Cancer Res"},{"key":"4658_CR54","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13000-023-01357-1","volume":"18","author":"APH Dyrbekk","year":"2023","unstructured":"Dyrbekk APH, Warsame AA, Suhrke P, Ludahl MO, Moe JO, Eide IJZ, Lund-Iversen M, Brustugun OT (2023) Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung. cancer Diagn Pathol 18:70. https:\/\/doi.org\/10.1186\/s13000-023-01357-1","journal-title":"cancer Diagn Pathol"},{"key":"4658_CR55","doi-asserted-by":"publisher","first-page":"4561","DOI":"10.3390\/cancers15184561","volume":"15","author":"W Cao","year":"2023","unstructured":"Cao W, Tang Q, Zeng J, Jin X, Zu L, Xu S (2023) A review of biomarkers and their clinical impact in resected early-stage non-small-cell lung cancer Cancers. (Basel) 15:4561. https:\/\/doi.org\/10.3390\/cancers15184561","journal-title":"(Basel)"},{"key":"4658_CR56","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.21037\/tlcr-23-470","volume":"12","author":"I Riano","year":"2023","unstructured":"Riano I, Dragnev KH, Phillips JD (2023) The beginning of the perioperative immunotherapy era in early-stage non-small cell lung cancer Transl. Lung Cancer Res 12:2359\u20132365. https:\/\/doi.org\/10.21037\/tlcr-23-470","journal-title":"Lung Cancer Res"},{"key":"4658_CR57","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","volume":"389","author":"H Wakelee","year":"2023","unstructured":"Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodriguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD, Investigators K- (2023) Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N Engl J Med 389:491\u2013503. https:\/\/doi.org\/10.1056\/NEJMoa2302983","journal-title":"N Engl J Med"},{"key":"4658_CR58","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N, CheckMate I (2022) Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer N. Engl J Med 386:1973\u20131985. https:\/\/doi.org\/10.1056\/NEJMoa2202170","journal-title":"Engl J Med"},{"key":"4658_CR59","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/ijms25010461","volume":"25","author":"W Andraus","year":"2023","unstructured":"Andraus W, Tustumi F, de Meira Junior JD, Pinheiro RSN, Waisberg DR, Lopes LD, Arantes RM, Rocha Santos V, de Martino RB, Carneiro D, Albuquerque LA (2023) Molecular profile of intrahepatic cholangiocarcinoma. Int J Mol Sci 25:461. https:\/\/doi.org\/10.3390\/ijms25010461","journal-title":"Int J Mol Sci"},{"key":"4658_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2022.11.006","volume":"179","author":"GS Roth","year":"2023","unstructured":"Roth GS, Neuzillet C, Sarabi M, Edeline J, Malka D, Lievre A (2023) Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine? Eur J Cancer 179:1\u201314. https:\/\/doi.org\/10.1016\/j.ejca.2022.11.006","journal-title":"Eur J Cancer"},{"key":"4658_CR61","doi-asserted-by":"publisher","first-page":"102649","DOI":"10.1016\/j.ctrv.2023.102649","volume":"122","author":"A Stenzinger","year":"2024","unstructured":"Stenzinger A, Vogel A, Lehmann U, Lamarca A, Hofman P, Terracciano L, Normanno N (2024) Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing. Cancer Treat Rev 122:102649. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102649","journal-title":"Cancer Treat Rev"},{"key":"4658_CR62","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","volume":"78","author":"G Kendre","year":"2023","unstructured":"Kendre G, Murugesan K, Brummer T, Segatto O, Saborowski A, Vogel A (2023) Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma. J Hepatol 78:614\u2013626. https:\/\/doi.org\/10.1016\/j.jhep.2022.11.030","journal-title":"J Hepatol"},{"key":"4658_CR63","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/pharmaceutics16010100","volume":"16","author":"A Shikalov","year":"2024","unstructured":"Shikalov A, Koman I, Kogan NM (2024) Targeted glioma therapy - clinical Trials and. future Dir Pharm 16:100. https:\/\/doi.org\/10.3390\/pharmaceutics16010100","journal-title":"future Dir Pharm"},{"key":"4658_CR64","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12943-022-01513-z","volume":"21","author":"K Yang","year":"2022","unstructured":"Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang Z, Dai Z, Zhang X, Zhang L, Peng Y, Ye W, Zeng W, Liu Z, Cheng Q (2022) Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer 21:39. https:\/\/doi.org\/10.1186\/s12943-022-01513-z","journal-title":"Mol Cancer"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-026-04658-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-026-04658-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-026-04658-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:38:18Z","timestamp":1785908298000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-026-04658-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":64,"alternative-id":["4658"],"URL":"https:\/\/doi.org\/10.1007\/s00428-026-04658-0","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"20 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FP, CD, and LQ are employees of Thermo Fisher Scientific.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}